Endocrine cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Endocrine cardiomyopathy is not a single disease but a clinical expression linking myocardial dysfunction to a demonstrable hormonal abnormality. In its strictest use, it requires a cardiac phenotype, a biologically plausible relationship with the endocrine disorder, and reasonable exclusion of alternative causes sufficient to explain the presentation. The mere coexistence of diabetes, thyroid disease or endocrine hypertension with heart failure does not establish causality. The etiologic diagnosis arises from integration, not from the label.

Hormones act on the heart through nuclear and membrane receptors, but also by modifying heart rate, vascular resistance, circulating volume, blood pressure, metabolism and the autonomic nervous system. An endocrine disorder can therefore cause true myocardial injury, precipitate latent heart disease, or produce predominantly hemodynamic decompensation without an autonomous cardiomyopathic substrate. These possibilities have different prognoses and treatments. The concept of multilevel causality is essential to avoid confusing a direct mechanism with comorbidity.

Reversibility after endocrine correction is a strong argument supporting causality, but it is not proof in isolation. During the same interval, tachycardia, blood pressure, congestion and ischemia are often treated as well, and each can improve function. Conversely, incomplete recovery does not exclude an endocrine origin because prolonged exposure may leave fibrosis or unmask a genetic predisposition. The temporal response must be interpreted together with all interventions performed.

The most convincing forms include dysfunction due to thyrotoxicosis, catecholamine cardiomyopathy associated with pheochromocytoma or paraganglioma, acromegalic hypertrophy, and rare hypocalcemic cardiomyopathy. Hypercortisolism, aldosteronism and diabetes mainly produce phenotypes in which myocardial, vascular and metabolic effects are inseparable. A critical nosology avoids presenting highly heterogeneous evidence as uniform.

Clinical definition and nosologic boundaries

A cardiomyopathy is traditionally a disease of the heart muscle not explained solely by coronary artery disease, valvular disease, congenital heart disease or loading conditions. This definition becomes problematic in endocrine disorders because high blood pressure, volume expansion and tachycardia are part of the causal mechanism rather than merely extraneous factors. Excluding them completely would erase a biologically relevant portion of the disease; ignoring them would attribute every abnormality to the hormone. The term endocrine-related phenotype is often more precise than an absolute category.

The phenotype may be hyperkinetic, hypertrophic, dilated or functionally restrictive, with preserved or reduced ejection fraction. The same hormonal excess changes its manifestations according to duration, intensity, age and cardiovascular reserve: early thyrotoxicosis increases cardiac output, whereas persistent tachyarrhythmia can lead to dilation and low output. Acromegaly likewise evolves from hypertrophy with impaired distensibility toward a rare advanced systolic phase. The phenotypic trajectory matters more than a single snapshot.

It is useful to distinguish myocardial disease, heart failure and remodeling. The first implies structural or cellular myocardial abnormalities; the second is a clinical syndrome defined by symptoms, signs and structural or functional abnormalities; the third describes changes in mass, geometry or tissue that may still be asymptomatic. A patient with aldosteronism and hypertrophy does not automatically have heart failure, whereas a patient with thyrotoxicosis may be congested even before a marked reduction in ejection fraction. Terminologic precision prevents overdiagnosis.

Endocrine disorders may also act as a second hit on genetic, ischemic or inflammatory cardiomyopathies. A sarcomeric variant may make the ventricle less tolerant of tachycardia, and silent coronary artery disease may become symptomatic during a thyrotoxic or catecholamine crisis. If dysfunction persists despite hormonal control, the search for an independent substrate must be reopened. The model of multiple determinants is clinically more realistic than an endocrine-versus-nonendocrine dichotomy.

Shared mechanisms and myocardial vulnerability

Direct endocrine effects include changes in the expression of contractile proteins, ion channels, calcium transporters and energy systems. Thyroid hormones, catecholamines, GH, IGF-I, cortisol, aldosterone and insulin activate different pathways but converge on cell growth, oxidative stress, mitochondrial function and extracellular matrix. Physiologic exposure supports homeostasis, whereas prolonged excess or deficiency converts adaptive signals into injury. Cardiomyocyte plasticity explains both remodeling and part of the reversibility.

The hemodynamic component is equally important. Reduced vascular resistance and increased volume in thyrotoxicosis, intermittent vasoconstriction in pheochromocytoma, sodium retention in acromegaly, hypertension in hypercortisolism and mineralocorticoid activation in aldosteronism impose very different loads. Blood pressure and heart rate convert hormonal exposure into cumulative myocardial work. The integrated load is not a removable confounder but a causal pathway that must be measured.

The microcirculation and endothelium mediate many phenotypes. Elevated catecholamines cause vasoconstriction, supply-demand imbalance and direct toxicity; diabetes and hypercortisolism promote endothelial dysfunction, inflammation and rarefaction; aldosterone promotes oxidative stress and perivascular fibrosis. Coronary angiography without stenosis excludes significant epicardial obstruction, not microvascular injury. Microvascular disease links metabolism and function without producing a unique imaging signature.

Thyroid: thyrotoxicosis, hyperthyroidism and hypothyroidism

Triiodothyronine increases transcription of contractile and calcium-regulatory proteins, adrenergic sensitivity, heart rate and contractility, while reducing systemic vascular resistance. Vasodilation activates sodium and water retention systems and expands plasma volume, so cardiac output and pulse pressure increase. This hyperdynamic state does not in itself equal cardiomyopathy. The thyrotoxic heart becomes pathologic when reserve, rhythm or myocardium cannot sustain the load.

Thyrotoxicosis denotes tissue exposure to an excess of thyroid hormones regardless of the source; hyperthyroidism instead requires increased synthesis and secretion by the gland. Graves disease, toxic nodular goiter, thyroiditis, exogenous excess and drugs require different etiologic treatments. Biochemical diagnosis starts with TSH and FT4, with FT3 when needed, and proceeds to antibodies, imaging or uptake testing according to context. Etiologic distinction prevents prescribing antithyroid drugs for destructive thyroiditis.

Manifestations include sinus tachycardia, widened pulse pressure, atrial fibrillation, exercise intolerance and congestion. Heart failure may occur with preserved ejection fraction because cardiac output cannot increase further, or with reduced ejection fraction due to tachycardia-induced cardiomyopathy, hormonal toxicity and prolonged loading. True dilated cardiomyopathy is rare compared with the frequency of thyrotoxicosis. Thyrotoxic systolic dysfunction remains a diagnosis of exclusion, not an inevitable consequence of elevated FT4.

Echocardiography may show a hyperkinetic state, atrial dilation, functional regurgitation, elevated pulmonary pressures, or dilation with low ejection fraction in advanced cases. Imaging has no pathognomonic pattern; CMR is reserved for discordant findings, suspected myocarditis or another cardiomyopathy and may show nonspecific edema or fibrosis. ECG and monitoring quantify arrhythmic burden, while natriuretic peptides reflect wall stress rather than etiology. Cardiac phenotyping should accompany biochemical control.

Treatment combines heart-rate control, correction of congestion and treatment of the thyroid cause. Beta-blockers reduce symptoms and the adrenergic response, but in low-output heart failure or shock a long-acting, non-titratable dose may precipitate collapse; in intensive care, esmolol permits a more controllable trial without turning caution into a guarantee of safety. Antithyroid drugs, radioiodine or surgery depend on the etiology and patient profile. The treatment sequence should be shared among endocrinology, cardiology and intensive care teams in unstable cases.

Thyroid storm is a clinical diagnosis of multiorgan dysfunction, not an extreme hormone value. It requires immediate treatment of the trigger and hormone excess, with supportive care, an appropriate antithyroid drug, iodine administered after blockade of hormone synthesis, glucocorticoids, and cautious control of the adrenergic response; cholestyramine, plasmapheresis or surgery may be used in refractory cases at expert centers. Cardiac involvement may dominate with pulmonary edema, arrhythmias or shock. The thyrotoxic emergency does not permit waiting for every result when clinical suspicion is high.

In hypothyroidism, heart rate, contractility and relaxation decrease, while systemic vascular resistance and sometimes diastolic blood pressure increase. Diastolic dysfunction, reduced exercise capacity and pericardial effusion are more common than systolic cardiomyopathy, which remains rare and requires exclusion of coronary artery disease and other causes. Elevated TSH with low FT4 confirms overt primary hypothyroidism, but critical illness and central hypothyroidism require different interpretations. Hypothyroid bradycardia should not be mistaken for proof of myocardial failure.

Levothyroxine corrects the deficiency, but the pace of titration takes age, coronary artery disease, arrhythmias and severity into account. Aggressive replacement may provoke ischemia or tachyarrhythmias in a vulnerable heart, whereas myxedema coma requires intensive care, parenteral thyroid hormone and glucocorticoid coverage until adrenal insufficiency is excluded. Functional recovery may take months. Restoration of euthyroidism should avoid both persistent deficiency and iatrogenic thyrotoxicosis.

Pheochromocytoma, paraganglioma and catecholamine excess

Secreting pheochromocytomas and paragangliomas can expose the heart to surges or persistent levels of norepinephrine, epinephrine and, less commonly, dopamine. Coronary and systemic vasoconstriction, tachycardia, pressure overload, microvascular ischemia, intracellular calcium excess and myocyte necrosis contribute to injury. The result ranges from chronic hypertrophy to severe acute dysfunction. Catecholamine toxicity therefore combines hemodynamic and cellular mechanisms.

The presentation may mimic myocardial infarction, myocarditis, dilated cardiomyopathy or a regional stress pattern. Its relationship with Takotsubo syndrome is important but not identical: the tumor may cause apical, midventricular or basal ballooning, global hypokinesia or a chronic dilated form. Pain, pulmonary edema, arrhythmias and shock may occur with high, normal or profoundly low blood pressure. Hemodynamic variability is a clue, not a sufficient criterion.

Suspicion increases with episodic headache, sweating, palpitations, pallor, tremor, paroxysmal or labile blood pressure, adrenal incidentaloma and a predisposing genetic syndrome. In unexplained acute presentations, hyperglycemia, leukocytosis and elevated lactate may reflect stress without being specific. Initial biochemical assessment uses plasma free metanephrines or fractionated urinary metanephrines, collected and interpreted under conditions that limit false positives from posture, medications or critical illness. Biochemical diagnosis generally precedes anatomic localization.

Echocardiography and CMR define the distribution of dysfunction, edema, thrombi and recovery, but no pattern identifies the tumor with certainty. Troponin may increase and BNP may be markedly elevated; coronary angiography is required when the probability of an acute coronary syndrome warrants it. Dysfunction that appears disproportionate to the coronary anatomy should broaden the differential diagnosis. Clinical-coronary discordance helps prevent a potentially curable tumor from remaining occult.

Multisystem crisis requires stabilization in a center with endocrinology, cardiology, anesthesia, surgery and intensive care. Titrated vasodilators and alpha blockade are adapted to blood pressure and perfusion; isolated beta-blockade before adequate alpha antagonism may worsen vasoconstriction, while in shock the sequence is even more complex and may require temporary mechanical support. Volume expansion must take edema and ventricular function into account rather than follow automatic rules. Preoperative stabilization normally precedes definitive resection.

Ventricular function often recovers within days or weeks when exposure ends, but chronic forms with fibrosis have a less predictable prognosis. Before surgery, recovery should be documented, arrhythmias controlled and hemodynamic risk planned; after resection, biochemical response and surveillance are confirmed according to genotype and recurrence risk. Rapid recovery does not justify stopping the tumor workup. Causal treatment requires treating the tumor in addition to normalization of the echocardiogram.

Acromegaly and GH/IGF-I-related remodeling

In acromegaly, chronic exposure to GH and IGF-I stimulates cardiomyocyte growth, protein synthesis, sodium retention and interstitial changes. The classic phenotype includes increased ventricular mass, often concentric geometry and impaired relaxation, with a possible early hyperkinetic phase and rare systolic dilation in late stages. The historical definition of acromegalic cardiomyopathy does not always separate the hormonal effect from hypertension, obstructive sleep apnea and diabetes. The somatotropic burden must be interpreted together with comorbidities.

Hypertrophy may occur even without documented hypertension, supporting a direct effect, but nocturnal blood pressure, arterial stiffness and sleep-apnea-related load are often underestimated. Diastolic dysfunction and reduced longitudinal strain may precede a decline in ejection fraction. Mitral or aortic valve disease and arrhythmias contribute to symptoms without being cardiomyopathy in the strict sense. Acromegaly phenotyping should therefore include valves, rhythm and sleep-disordered breathing.

Diagnosis of the endocrine disorder is based on clinical features and IGF-I interpreted using age-validated reference ranges; discordant results require repeat testing and, in selected settings, GH suppression testing. Pituitary MRI localizes the adenoma after biochemical confirmation. On the cardiac side, the 2026 consensus recommends a baseline assessment of function and morphology, then individualized follow-up according to clinical characteristics. The baseline profile provides the reference for distinguishing biochemical remission from organ recovery.

Echocardiography measures mass, geometry, atrial size, diastolic function, valves and strain; CMR is useful when acoustic windows are inadequate or more reproducible characterization of mass and tissue is needed. Focal or diffuse fibrosis may explain failure to normalize, but mapping and extracellular volume are not diagnostic criteria for acromegaly. ECG and monitoring are guided by palpitations, syncope and baseline abnormalities. Multimodal characterization should answer a clinical question rather than document every subclinical abnormality.

Rapid and durable control of GH and IGF-I is the main causal intervention. Transsphenoidal surgery is often first-line therapy for a resectable adenoma, while somatostatin analogues, pegvisomant, cabergoline in selected cases, and radiotherapy are sequenced according to residual disease, activity and individual features. Hyperkinesis, function and part of the hypertrophy often improve, but late injury may persist; the evidence does not justify choosing a drug solely for a presumed superior cardiac benefit. Biochemical control does not replace specific treatment of blood pressure, sleep apnea, diabetes and heart failure.

Follow-up separately assesses disease activity, pituitary mass and cardiac complications. A normalized ejection fraction does not demonstrate regression of fibrosis or valvular disease, while residual mass does not necessarily imply symptoms. Medications may introduce their own problems, such as glycemic abnormalities or QT prolongation with some treatments, requiring targeted monitoring. Organ remission is an outcome distinct from laboratory normalization alone.

Hypercortisolism and primary aldosteronism

Endogenous hypercortisolism increases cardiovascular mortality through a combination of hypertension, visceral adiposity, insulin resistance, dyslipidemia, a prothrombotic state and vascular dysfunction. Cortisol and glucocorticoids directly affect cardiomyocytes, matrix and adrenergic responses, but in practice it is difficult to quantify the component independent of loading conditions. The most common phenotypes are concentric hypertrophy, increased mass and diastolic dysfunction, whereas a severe dilated form is rare. Cortisol-related heart disease is therefore predominantly systemic and multifactorial.

Cushing syndrome should be suspected when discriminatory features, rapid progression or unusual comorbidities occur together, not in response to obesity alone. After excluding exogenous exposure, validated initial tests include urinary free cortisol, late-night salivary cortisol or the 1-mg dexamethasone suppression test, selected according to context and repeated when necessary. ACTH and imaging follow biochemical confirmation to define the source. The cortisol pathway avoids mistaking radiologic incidentalomas for causes.

Mild autonomous cortisol secretion in adrenal incidentalomas is associated with a greater cardiometabolic burden, but it does not have a specific cardiomyopathy identifiable by imaging. European guidelines use dexamethasone suppression and consider age, frailty and comorbidity in therapeutic decisions. Attributing ventricular dysfunction to a modest suppression abnormality requires particular caution. Causality in MACS remains probabilistic and should avoid surgical overtreatment.

Resection of the source is preferred when feasible in endogenous Cushing syndrome, with cortisol-lowering drug therapy when surgery is not possible, incomplete or requires bridging. Correction of hypercortisolism can improve blood pressure, metabolism and cardiac geometry, but risk does not immediately return to zero and some abnormalities persist. During and after treatment, adrenal insufficiency must be prevented and thrombosis, infections, diabetes and heart failure actively managed. Cortisol normalization is necessary but does not erase cardiovascular memory.

In primary aldosteronism, aldosterone secretion is inappropriate relative to renin and causes sodium retention, potassium loss and mineralocorticoid-receptor activation. Blood-pressure-matched cohorts show greater hypertrophy, atrial fibrillation, fibrosis and cardiovascular risk than primary hypertension, supporting injury beyond the pressure value alone. However, hypertension remains a dominant part of the mechanism, making it inappropriate to diagnose cardiomyopathy from ventricular mass alone. The term mineralocorticoid remodeling better describes many cases.

The 2025 Endocrine Society guidelines conditionally suggest screening all individuals with hypertension using aldosterone and renin; potassium accompanies sampling to permit correct interpretation of aldosterone, but is not the screening test. Feasibility and priority depend on local resources. Medications, sodium intake, renal function and assay method affect the results. Confirmation and lateralization follow pretest probability and therapeutic goals, with adrenal venous sampling in appropriate surgical candidates. Aldosterone diagnostics cannot be reduced to a ratio detached from context.

Adrenalectomy is indicated for lateralized unilateral disease in surgical candidates, whereas mineralocorticoid-receptor antagonists treat bilateral or nonsurgical disease. If blood pressure remains high and renin is suppressed, the guidelines suggest increasing specific therapy until renin rises from baseline, without specifying a target value; when blood pressure is already controlled, the efficacy of titrating treatment solely to increase renin remains uncertain. Potassium and renal function require monitoring; the initial fall in GFR may reflect correction of hyperfiltration. Ventricular mass and diastolic function may improve, but the extent depends on disease duration and blood-pressure control. Aldosterone-specific therapy is more rational than nonspecific adjustment of antihypertensive therapy alone.

Diabetes and the controversy surrounding diabetic cardiomyopathy

The term diabetic cardiomyopathy was introduced to describe heart failure in people with diabetes without coronary artery disease, hypertension, valvular disease or other recognizable causes. Today it denotes a myocardial process attributed to the diabetic metabolic environment, but there are no universally accepted international diagnostic criteria. Most patients with type 2 diabetes also have obesity, hypertension, kidney disease and atherosclerosis, each capable of remodeling the heart. The exclusion-based definition remains useful for research but fragile in the individual patient.

Diabetes increases the risk of heart failure with both preserved and reduced ejection fraction. The former phenotype is promoted by obesity, systemic inflammation, vascular and microvascular stiffness; the latter may emerge with coronary artery disease, nephropathy, metabolic toxicity or an independent substrate. A mandatory sequence from subclinical diastolic dysfunction to systolic dilation has not been demonstrated for everyone. Diabetic heterogeneity prevents construction of a single natural history.

Proposed mechanisms include loss of metabolic flexibility, increased fatty-acid utilization, lipotoxicity, advanced glycation end products, oxidative stress, mitochondrial dysfunction and altered calcium homeostasis. Insulin resistance, inflammation and neurohormonal activation promote hypertrophy and collagen deposition. These pathways are well supported by experimental models, but their individual clinical measurement is limited. Metabolic biology provides plausibility without yet providing a causal test.

Microangiopathy, endothelial dysfunction and capillary rarefaction reduce reserve and disrupt coupling between supply and metabolism. Autonomic neuropathy alters heart rate, variability and perception of ischemia, while kidney disease amplifies volume, anemia, inflammation and mineral disorders. The diabetic myocardium is therefore exposed to simultaneous signals, not to a single glucose toxin. The cardiorenal-metabolic network makes complete separation of the organs artificial.

Echocardiography may show concentric remodeling, atrial enlargement, impaired relaxation and reduced global longitudinal strain with a normal ejection fraction. These findings increase the likelihood of subclinical injury but are nonspecific and common in hypertension and obesity. CMR measures volumes, perfusion, fat and fibrosis with LGE, T1 and extracellular volume, but no threshold defines diabetic cardiomyopathy. Subclinical imaging stratifies risk more readily than it establishes causation.

Natriuretic peptides and high-sensitivity troponin may identify risk and injury, but obesity and treatment modify their levels. A low natriuretic peptide level lowers the probability of overt heart failure without always excluding HFpEF in obesity; persistent elevation requires evaluation for ischemia, atrial fibrillation and kidney disease. No biomarker separates diabetic cardiomyopathy from other etiologies. Biomarker-guided stratification must lead to clinical decisions, not to a new automatic label.

The evaluation systematically searches for symptoms and signs of heart failure and determines the likelihood of coronary artery disease, which may be silent in diabetes. Exclusion does not require invasive angiography in everyone, but an anatomic or functional test consistent with symptoms, risk and therapeutic consequences. Ambulatory blood pressure, albuminuria, GFR, rhythm and sleep apnea complete the picture. The diabetic differential diagnosis is as important as demonstrating abnormal function.

There is no approved therapy that selectively treats diabetic cardiomyopathy as a distinct entity. In patients with heart failure, SGLT2 inhibitors reduce hospitalizations and cardiovascular risk across the spectrum of ejection fraction, regardless of whether the dysfunction is called diabetic; in type 1 diabetes, the risk of ketoacidosis prevents routine use for this indication. Other therapies follow the heart-failure phenotype, renal function and comorbidities. Demonstrated clinical benefit takes precedence over mechanistic hypotheses.

Multifactorial control includes individualized glycemia, blood pressure, lipids, weight, physical activity, sleep, renal function and smoking cessation. GLP-1 receptor agonists reduce atherosclerotic events and body weight in appropriate populations but do not replace heart-failure therapy; thiazolidinediones promote fluid retention and are avoided in symptomatic heart failure. Very aggressive glucose lowering has not been shown by itself to reverse the myocardial phenotype. Cardiorenal-metabolic care should pursue outcomes, not HbA1c alone.

Hypocalcemia, hypoparathyroidism and other endocrine axes

Extracellular calcium supports excitation-contraction coupling, the action-potential plateau and systolic force. Severe and prolonged hypocalcemia can cause QT prolongation, arrhythmias and a rare dilated cardiomyopathy, described mainly in adult hypoparathyroidism and severe vitamin D deficiency in children. The true frequency is unknown because the evidence comes mainly from case series and reports. Hypocalcemic cardiomyopathy is rare but important because it is potentially reversible.

Total calcium concentration should be corrected for albumin or, when possible, replaced by ionized calcium measurement in critically ill patients. PTH, phosphate, magnesium, creatinine and 25-hydroxyvitamin D identify hypoparathyroidism, magnesium deficiency, kidney disease or nutritional deficiency. A low or inappropriately normal PTH in hypocalcemia supports hypoparathyroidism, whereas severe hypomagnesemia can reduce PTH secretion and action. Mineral diagnosis requires more than total calcium alone.

Tetany, seizures, laryngospasm, markedly prolonged QT, arrhythmia or heart failure with symptomatic hypocalcemia require monitored intravenous calcium and magnesium correction, followed by treatment of the cause. In chronic hypoparathyroidism, oral calcium and active vitamin D generally target calcium in the low-normal range while limiting hypercalciuria and renal injury; PTH therapy is reserved for selected indications. Recovery of function may be slow and does not eliminate the need for cardiologic therapy. Electrolyte correction must avoid both persistent hypocalcemia and iatrogenic hypercalcemia.

Other endocrine axes have cardiovascular associations but weaker evidence for an autonomous cardiomyopathy. GH deficiency, adrenal insufficiency, hyperparathyroidism and gonadal disorders alter body composition, blood pressure, metabolism or vascular risk without a clinically specific myocardial phenotype in most cases. Hemochromatosis, amyloidosis and mitochondrial diseases may present with endocrine abnormalities but belong to distinct infiltrative, genetic or metabolic etiologies. Classificatory discipline prevents every relationship between hormone and heart from being included in the same category.

Etiologic diagnostic pathway and imaging

The first task is to determine whether a cardiac syndrome exists and how urgent it is. History, examination, ECG, oxygen saturation, troponin, natriuretic peptides, renal function, electrolytes and echocardiography distinguish congestion, shock, arrhythmia and acute myocardial injury. Stabilization should not wait for the complete endocrine diagnosis. Hemodynamic priority comes before nosologic refinement.

The endocrine history looks for weight loss and tremor, cold intolerance, adrenergic crises, acral changes, bruising and proximal weakness, resistant hypertension, polyuria, neck surgery and hormone medications. No isolated sign is sufficient, but the constellation changes pretest probability. Glucocorticoids by every route, thyroid hormones, amiodarone, lithium, supplements and sympathomimetic substances should be documented. Hidden pharmacology is a common cause of apparently spontaneous presentations.

An indiscriminate endocrine panel generates false positives and incidentalomas. TSH and calcium are reasonably included in the evaluation of many unexplained dysfunctions; HbA1c and glucose define the metabolic context. Metanephrines, IGF-I, cortisol testing and the aldosterone-renin ratio are added according to phenotype, blood pressure, electrolytes and clinical signs. Targeted testing preserves sensitivity without sacrificing specificity.

Echocardiography defines geometry, systolic and diastolic function, valves, pressures and complications, but rarely identifies the responsible hormone on its own. Strain can detect early dysfunction, provided it is not converted into an etiologic criterion. Comparison with prior examinations clarifies whether the abnormality predates the recognized endocrine disorder. Imaging chronology is often more informative than a single highly precise measurement.

CMR is indicated when the phenotype remains uncertain, echocardiography is inadequate, or ischemia, myocarditis, infiltration, scar and thrombus must be distinguished. Edema in catecholamine excess, fibrosis in acromegaly and increased extracellular volume in diabetes are possible observations, not diagnostic signatures. Absence of LGE does not exclude diffuse abnormalities, whereas persistent LGE lowers the expectation of complete reversibility. Tissue characterization guides prognosis and differential diagnosis more than hormone measurement.

Coronary artery disease, primary hypertension, valvular disease, myocarditis, sarcoidosis, amyloidosis, alcohol, chemotherapeutic agents and tachycardia-induced cardiomyopathy should be assessed according to probability. An abnormal hormone does not make angiography unnecessary when the presentation suggests an acute coronary syndrome. Endomyocardial biopsy is reserved for standard indications in which histology can change therapy, not for routine confirmation of endocrine cardiomyopathy. A complete differential diagnosis protects against attribution bias.

If important dysfunction persists after endocrine and hemodynamic control, rhythm, ischemia, adherence, toxins and genetic causes should be reassessed. Pedigree, age at onset, conduction disease, ventricular arrhythmias and fibrosis may justify genetic testing even in the presence of an endocrine trigger. Finding a variant does not negate the effect of the hormone, but it changes family surveillance and the risk threshold. Post-correction reassessment more clearly separates trigger from substrate.

Cardiologic therapy, emergencies and interactions

Therapy has two simultaneous axes: remove the endocrine exposure and treat the cardiovascular phenotype. Diuretics, renin-angiotensin system inhibition, beta-blockade, mineralocorticoid antagonism, SGLT2 inhibitors and devices are used according to guidelines for ejection fraction, blood pressure, renal function and rhythm, without assuming that reversibility makes treatment unnecessary. Titration takes specific physiology into account because vasodilation, bradycardia or electrolyte shifts may be poorly tolerated. Dual causal therapy reduces the risk of passive waiting.

Arrhythmias require correction of the trigger, but also immediate risk management. In thyrotoxic atrial fibrillation, rate control and anticoagulation follow hemodynamic stability and thromboembolic risk, without assuming that rhythm will normalize soon enough to prevent stroke. QT prolongation due to hypocalcemia requires ionic correction and medication review; catecholamine-related arrhythmias require crisis control. Electrical risk is treated before the reversible component is known.

In shock it is dangerous to apply a single algorithm to all endocrine disorders. Beta-blockade may be necessary in thyroid storm but harmful if it depresses an already critically low output; in pheochromocytoma isolated beta-blockade promotes unopposed vasoconstriction; in adrenal insufficiency glucocorticoids and calibrated volume replacement are required. Vasopressors and inotropes may interact with endogenous catecholamine excess and require advanced monitoring. The physiology of shock must guide every titratable drug.

Temporary mechanical support can provide a bridge to recovery in fulminant catecholamine-related or thyrotoxic forms when medical and ventilatory therapy cannot maintain perfusion. Selection considers the ventricle involved, arrhythmias, coagulation, vascular access and the possibility of rapid causal control. It does not replace endocrine treatment and carries substantial risks, so it belongs in expert centers. The bridge to reversibility is a selective strategy, not an assumed property of the device.

Therapeutic interactions should be anticipated. Correction of hyperthyroidism changes anticoagulant requirements and heart rate; mineralocorticoid antagonists and treatment of aldosteronism alter potassium and GFR; acromegaly drugs affect glycemia and sometimes QT; thyroid replacement may unmask ischemia. Rapid volume changes after endocrine surgery also require review of diuretics. Therapeutic reconciliation is an integral part of multidisciplinary care.

Follow-up, reversibility and prognosis

Follow-up separately measures endocrine control, symptoms, volume status, ventricular function, rhythm and tissue injury. After a catecholamine crisis, imaging may be repeated at short intervals, whereas in stable acromegaly it depends on phenotype and comorbidities. In thyrotoxicosis with dysfunction, reassessment after achieving euthyroidism documents recovery without waiting indefinitely. Phenotype-guided surveillance replaces automatic schedules.

Normalization of ejection fraction does not always end the risk. Atrial dilation, fibrosis, arrhythmias, valvular disease and vascular disease may persist; withdrawal of heart-failure therapy should be considered with particular caution in recovered phenotypes. Conversely, repeated imaging without a decision that could follow increases costs and incidental findings. Cardiac remission requires clinical, structural and etiologic stability.

Prognosis is favorable when a rapidly correctable cause is recognized before fibrosis develops and there is no underlying heart disease. Longer exposure, shock, low ejection fraction, LGE, arrhythmias, coronary artery disease, kidney disease and incomplete endocrine control worsen outcomes. In hypercortisolism and diabetes, risk may remain elevated even after numerical improvement because vascular and metabolic injury is cumulative. Residual prognosis depends on what the hormone has left behind, not only on its current level.

Research still needs to validate shared definitions, imaging thresholds and reassessment timing. Randomized studies comparing endocrine treatments for cardiomyopathy outcomes are lacking, and much knowledge derives from selected cohorts or striking case reports. Mapping techniques, proteomics and digital phenotyping are promising but require evidence of clinical utility beyond association. The certainty of evidence must remain distinct from biological plausibility.

Best practice ultimately consists of formulating a graded conclusion: cardiomyopathy probably caused by, likely precipitated by, or merely associated with the endocrine disorder. This wording makes explicit what is known, what remains to be excluded and which future observations could change the judgment. It allows decisive treatment without turning a hypothesis into an immutable diagnosis. Diagnostic transparency is particularly important in a field lacking a single gold standard.